Long-term efficacy and safety of raltegravir in the management of HIV infection

References

• NME drug and new biologic approvals in 2007 [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration [updated February 10, 2009]. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandap-proved/drugandbiologicapprovalreports/ucm081690.htmAccessed October 31, 2013
   Google Scholar
• US Food and Drug AdministrationFDA approves new combination pill for HIV treatment for some patients [press release]Silver Spring, MDUS Food and Drug Administration2012 [August 27; updated August 29, 2012]. Available from: http://www.fda.gov/news-events/newsroom/pressannouncements/ucm317004.htmAccessed October 31, 2013
   Google Scholar
• US Food and Drug AdministrationFDA approves new drug to treat HIV infection [press release]Silver Spring, MDUS Food and Drug Administration2013 [August 12; updated August 13, 2013]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm364744.htmAccessed October 31, 2013
   Google Scholar
• US Food and Drug AdministrationIsentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients [press release]Silver Spring, MDUS Food and Drug Administration [updated July 13, 2009]. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm171317.htmAccessed October 31, 2013
   Google Scholar
• US Food and Drug AdministrationFDA expands use of HIV drug Isentress to children and adolescents [press release]Silver Spring, MDUS Food and Drug Administration2011 [December 21]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm284473.htmAccessed October 31, 2013
   Google Scholar
• LennoxJLDeJesusELazzarinASTARTMRK investigatorsSafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet2009374969279680619647866
   PubMed Web of Science ®Google Scholar
• SteigbigelARCooperDAKumarPNBENCHMRK Study TeamsRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• RockstrohJKDeJesusELennoxJLSTARTMRK InvestigatorsDurable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJ Acquir Immune Defic Syndr2013631778523412015
   PubMed Web of Science ®Google Scholar
• EronJJCooperDASteigbigelRTBENCHMRK Study TeamsEfficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomized placebo-controlled trialsLancet Infect Dis201313758759623664333
   PubMed Web of Science ®Google Scholar
• SummaVPetrocchiABonelliFDiscovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infectionJ Med Chem200851185843585518763751
   PubMed Web of Science ®Google Scholar
• ShimuraKKodamaESakagamiYBroad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)J Virol200882276477417977962
   PubMed Web of Science ®Google Scholar
• JohnsBAKawasujiTWeatherheadJGCarbamoyl pyridine HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744)J Med Chem201356145901591623845180
   PubMed Web of Science ®Google Scholar
• PommierYJohnsonAAMarchandCIntegrase inhibitors to treat HIV/AIDSNat Rev Drug Discov20054323624815729361
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAPetryASSafety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsClin Pharmacol Ther200883229329917713476
   PubMed Web of Science ®Google Scholar
• BlancoJLVargheseVRheeSYGatellJMShaferRWHIV-1 integrase inhibitor resistance and its clinical implicationsJ Infect Dis201120391204121421459813
   PubMed Web of Science ®Google Scholar
• WenningLAndersonMPetryARaltegravir (RAL) dose proportionality and effect of food (abstract H-1046)47th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, CASeptember 17–20, 2007
   Google Scholar
• CattaneoDGervasoniCMeravigliaPInter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjectsJ Antimicrob Chemother201267246046422127581
   PubMed Web of Science ®Google Scholar
• KassahunMMacIntoshICuiDMetabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeDrug Metab Dispos20073591657166317591678
   PubMed Web of Science ®Google Scholar
• WenningLAPetryASKostJTPharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsClin Pharmacol Ther200985662362719279563
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAMistryGCAtazanavir modestly increases plasma levels of raltegravir in healthy subjectsClin Infect Dis200847113714018513146
   PubMed Web of Science ®Google Scholar
• CattaneoDRipamontiDBaldelliSCozziVContiFClementiEExposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patientsTher Drug Monit201032678278620926993
   PubMed Web of Science ®Google Scholar
• WenningLAHanleyWDBrainardDMEffect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirAntimicrob Agents Chemother20095372852285619433563
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLAPetryASMinimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirAntimicrob Agents Chemother200852124338434318838589
   PubMed Web of Science ®Google Scholar
• AndersonMSKakudaTNHanleyWMinimal pharmacokinetic interaction between the human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsAntimicrob Agents Chemother200852124228423218838586
   PubMed Web of Science ®Google Scholar
• Barrail-TranAYazdanpanahYFagardCLack of Interaction between etravirine and raltegravir plus darunavir/ritonavir when combined in treatment-experienced patients: a substudy of the ANRS 139 TRIO trial (abstract 606)17th Conference on Retroviruses and Opportunistic InfectionsSan Francisco, CAFebruary 16–19, 2010
   Google Scholar
• AndrewsEGluePFangJCrownoverPTresslerRDamleBAssessment of the pharmacokinetics of co-administered maraviroc and raltegravirBr J Clin Pharmacol2010691515720078612
   PubMed Web of Science ®Google Scholar
• WenningLAFriedmanEJKostJTLack of a significant drug interaction between raltegravir and tenofovirAntimicrob Agents Chemother20085293253325818625763
   PubMed Web of Science ®Google Scholar
• HanleyWDWenningLAMoreauAEffect of tipranavir-ritonavir on pharmacokinetics of raltegravirAntimicrob Agents Chemother20095372752275519398643
   PubMed Web of Science ®Google Scholar
• CooperDASteigbigelRTGatellJMBENCHMRK Study TeamsSubgroup and resistance analyses of raltegravir for resistant HIV-1 infectionN Engl J Med2008359435536518650513
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLANguyenBYEffects of omeprazole on plasma levels of raltegravirClin Infect Dis200948448949219143531
   PubMed Web of Science ®Google Scholar
• RhameFMatsonMWoodDEffects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV infected persons (abstract PE4.1/1)12th Europeans AIDS ConferenceCologneNovember 11–14, 2009
   Google Scholar
• KiserJJBumpassJBMeditzALEffect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteersAntimicrob Agents Chemother201054124999500320921313
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoEProtocol 004 Part II Study TeamRapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyJ Acquir Immune Defic Syndr200746212513317721395
   PubMed Web of Science ®Google Scholar
• GotuzzoEMarkowitzMRatanasuwanWProtocol 004 Study TeamSustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004)J Acquir Immune Defic Syndr2012611737722743596
   PubMed Web of Science ®Google Scholar
• RaffiFRachlisAStellbrinkHJSPRING-2 Study GroupOnce-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 studyLancet2013381986873574323306000
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanESPRING-2 Study GroupOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trialLancet Infect Dis2013131192793524074642
   PubMed Web of Science ®Google Scholar
• YoungBVanigTDeJesusESHIELD Study Team96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trialHIV Clin Trials201112422823322044859
   PubMed Web of Science ®Google Scholar
• ReynesJTrinhRPulidoFLopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS studyAIDS Res Hum Retroviruses201329225626522730929
   PubMed Web of Science ®Google Scholar
• GatellJMKatlamaCGrinsztejnBProtocol 005 TeamLong-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJ Acquir Immune Defic Syndr201053445646320306554
   PubMed Web of Science ®Google Scholar
• GrinsztejnBNguyenAYKatlamaCProtocol 005 TeamSafety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialLancet200736995691261126917434401
   PubMed Web of Science ®Google Scholar
• ElionRMolinaJMRamón ArribasLópez JStudy 145 TeamA randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsJ Acquir Immune Defic Syndr201363449449723807156
   PubMed Web of Science ®Google Scholar
• CapettiALandonioSMeravigliaP96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicenter Italian experiencePLoS One20127e3922222808029
   PubMed Web of Science ®Google Scholar
• FagardCColinCCharpentierCANRS 139 TRIO Trial GroupLong-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trialJ Acquir Immune Defic Syndr201259548949322293546
   PubMed Web of Science ®Google Scholar
• NguyenACalmyADelhumeauCA randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER) studyAIDS201125121481148721593661
   PubMed Web of Science ®Google Scholar
• GallienSBraunJDelaugerreCEASIER ANRS 138 Study GroupEfficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trialJ Antimicrob Chemother20116692099210621712241
   PubMed Web of Science ®Google Scholar
• MartinezELarrousseMLlibreJMSPIRAL Study GroupSubstitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyAIDS201024111697170720467288
   PubMed Web of Science ®Google Scholar
• EronJJYoungBCooperDASWITCHMRK 1 and 2 investigatorsSwitch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicenter, double-blind, randomized controlled trialsLancet2010375971239640720074791
   PubMed Web of Science ®Google Scholar
• De CastroNBraunJCharreauIEASIER ANRS 138 Study GroupSwitch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialClin Infect Dis20094981259126719757993
   PubMed Web of Science ®Google Scholar
• TownerWKleinDKerriganHLFollansbeeSYuKHorbergMVirologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER studyJ Acquir Immune Defic Syndr200951436737319487951
   PubMed Web of Science ®Google Scholar
• Isentress® (raltegravir) [package insert]Whitehouse Station, NJMerck Sharp and Dohme Corp.2011
   Google Scholar
• MadedduGMenzaghiBRicciECISAI GroupRaltegravir central nervous system tolerability in clinical practice: results from a multicenter observational studyAIDS201226182412241523032413
   PubMed Web of Science ®Google Scholar
• TsaiWJLeeSSTsaiHCRapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimenJ Microbiol Immunol Infect Epub4202013
   Google Scholar
• CroceFVitelloPDalla PriaARivaAGalliMAntinoriSSevere raltegravir-associated rhabdomyolysis: a case report and review of the literatureInt J STD AIDS2010211178378521187364
   PubMed Web of Science ®Google Scholar
• LeeFJAminJBlochMPettSLMarriottDCarrASkeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adultsJ Acquir Immune Defic Syndr201362552553323274936
   PubMed Web of Science ®Google Scholar
• MonteiroPPerezIPichJGatellJMMartinezECreatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort studyJ Antimicrob Chemother201368240440823109185
   PubMed Web of Science ®Google Scholar
• Isentress (raltegravir potassium) tablet and chewable tablet [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2013 [updated November 14, 2013]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm360369.htmAccessed September 20, 2013
   Google Scholar
• MessiaenPWensingAMFunANijhuisMBrusselaersNVandekerckhoveLClinical use of HIV integrase inhibitors: a systematic review and meta-analysisPLoS One201381e5256223341902
   PubMed Web of Science ®Google Scholar
• SaumoyMSánchez-QuesadaJLMartínezELDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudyAtherosclerosis2012225120020723017355
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsDepartment of Health and Human Services [updated February 12, 2013]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdfAccessed October 10, 2013
   Google Scholar
• ThompsonMAAbergJAHoyJFAntiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelJAMA2012308438740222820792
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society Guidelines Version 7.0European AIDS Clinical Society2013 Available from https://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdfAccessed January 29, 2014
   Google Scholar
• Guidelines for the Use of Antiretroviral Agents in Pediatric HIV InfectionPanel on Antiretroviral Therapy and Medical Management of HIV-Infected Children [updated November 5, 2012]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdfAccessed October 10, 2013
   Google Scholar
• EronJJJrRockstrohJKReynesJQDMRK InvestigatorsRaltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialLancet Infect Dis2011111290791521933752
   PubMed Web of Science ®Google Scholar
• RizkMLHangYLuoWLPharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsAntimicrob Agents Chemother20125663101310622430964
   PubMed Web of Science ®Google Scholar
• Tivicay® (dolutegravir) [package insert]Research Triangle Park, NCViiV Healthcare2013
   Google Scholar